• Bionano Genomics flagged newly published, peer-reviewed clinical research in Modern Pathology on optical genome mapping in T-cell acute lymphoblastic leukemia.
• Results were already presented via publication, positioning the technology as a higher-yield alternative to conventional cytogenetic testing in this setting.
• The study found the approach identified disease-related genomic abnormalities in nearly all cases, reducing the number of patients left without an actionable genetic explanation.
• Researchers also reported additional findings missed by standard workflows, supporting more complete subtype classification and potential new research targets.
• Data came from a 91-patient, head-to-head comparison versus karyotyping and next-generation sequencing, supporting a streamlined single-workflow strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bionano Genomics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605260800PRIMZONEFULLFEED9726101) on May 26, 2026, and is solely responsible for the information contained therein.